🇫🇷 IPN.PA — Ipsen S.A.

Salud Mantener
← Volver

Precio actual

155,80 EUR

Máx. histórico

172,90

182 días

Caída desde máximo

-9,89%

Rango 52 semanas

115,60 – 174,00

Variación hoy

+1,70%

Cierre anterior

153,20

Rango de hoy

153,30 – 155,90

Volumen hoy

107.342

Peor caída histórica

-75,62%

30/08/2018 → 18/03/2020

Recuperado en 2157 días

Volatilidad anualizada ⓘ

30,51%

Información
Nombre completo
Ipsen S.A.
Divisa
EUR
Mercado
Paris
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
5.535
PER ⓘ
25,21 (puede no estar actualizado)
Dividend yield
1,04% (puede no estar actualizado)
Precio objetivo analistas
161,92 EUR (puede no estar actualizado)
Primera cotización
07/12/2005
Precio actualizado
hace 18 horas
Sobre la empresa

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Dividendos repartidos Total últimos 12 meses: 1,6000 EUR · Yield: 1,03%
Fecha de pago Importe por participación
03/06/2026 1,6000 EUR
04/06/2025 1,4000 EUR
30/05/2024 1,2000 EUR
02/06/2023 1,2000 EUR
31/05/2022 1,2000 EUR
31/05/2021 1,0000 EUR
03/06/2020 1,0000 EUR
31/05/2019 1,0000 EUR
04/06/2018 1,0000 EUR
09/06/2017 0,8500 EUR
02/06/2016 0,8500 EUR
29/05/2015 0,8500 EUR
09/06/2014 0,8000 EUR
05/06/2013 0,8000 EUR
06/06/2012 0,8000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/02/2015 43,60 43,60 43,07 43,40 -0,37% 1,22% 38.462
13/02/2015 43,60 43,85 43,41 43,56 +0,22% 1,02% 43.168
12/02/2015 43,30 43,59 42,88 43,46 +0,37% 1,64% 55.765
11/02/2015 43,60 43,60 43,00 43,30 -0,55% 1,38% 71.072
10/02/2015 42,74 43,74 42,65 43,54 +2,30% 2,55% 97.198
09/02/2015 42,51 42,79 42,08 42,56 +0,12% 1,67% 142.633
06/02/2015 42,85 42,98 42,40 42,51 -0,71% 1,34% 134.909
05/02/2015 42,67 43,06 42,31 42,82 +0,36% 1,76% 67.544
04/02/2015 43,55 43,66 42,52 42,66 -3,05% 2,62% 109.711
03/02/2015 44,20 44,31 43,61 44,00 -0,34% 1,57% 107.581
02/02/2015 45,14 45,20 43,71 44,15 -2,11% 3,30% 88.280
30/01/2015 45,51 45,55 44,76 45,10 -0,87% 1,74% 69.116
29/01/2015 45,03 45,50 44,95 45,50 +1,10% 1,21% 47.902
28/01/2015 45,00 45,23 44,44 45,00 +0,06% 1,74% 35.443
27/01/2015 45,40 45,40 44,46 44,98 -0,78% 2,07% 50.525
26/01/2015 44,40 45,50 44,40 45,33 +2,20% 2,48% 82.958
23/01/2015 43,58 44,40 43,58 44,36 +1,92% 1,88% 95.520
22/01/2015 44,10 44,24 42,83 43,52 -1,14% 3,20% 87.614
21/01/2015 43,50 44,20 43,42 44,02 +1,20% 1,79% 102.084
20/01/2015 44,93 45,10 42,17 43,50 -3,01% 6,52% 198.310
19/01/2015 45,00 45,10 44,35 44,85 -0,22% 1,68% 42.155
16/01/2015 44,57 45,12 44,08 44,95 +1,03% 2,33% 56.856
15/01/2015 44,60 44,79 43,36 44,49 -0,13% 3,21% 56.680
14/01/2015 44,51 44,88 44,01 44,55 +0,01% 1,97% 77.311
13/01/2015 45,04 45,50 44,31 44,55 -1,26% 2,64% 68.386
12/01/2015 43,87 45,49 43,87 45,12 +3,44% 3,69% 94.391
09/01/2015 43,64 43,93 43,57 43,62 +0,26% 0,83% 108.967
08/01/2015 42,80 43,70 42,80 43,50 +1,85% 2,10% 126.177
07/01/2015 42,69 43,01 42,41 42,71 +0,12% 1,41% 106.407
06/01/2015 42,60 43,14 42,31 42,66 +0,11% 1,95% 61.631